Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05247905

Title field or adapter rule

{'original_value': 'Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.884477+00:00

Published At

2026-10-20T00:00:00+00:00

Record Updated At

2026-10-20

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Pancreatic Neuroendocrine Tumor", "Unresectable Pancreatic Neuroendocrine Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-20", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05247905"

protocolSection.identificationModule.officialTitle

"Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Metastatic Pancreatic Neuroendocrine Tumor (protocolSection.conditionsModule.conditions)
• Unresectable Pancreatic Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm I (lutetium Lu 177 dotatate)'], 'description': 'Given IV', 'name': 'Lutetium Lu 177 Dotatate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm II (capecitabine, temozolomide)'], 'description': 'Given PO', 'name': 'Capecitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm II (capecitabine, temozolomide)'], 'description': 'Given PO', 'name': 'Temozolomide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (lutetium Lu 177 dotatate)', 'Arm II (capecitabine, temozolomide)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm I (lutetium Lu 177 dotatate)'], 'description': 'Ancillary studies', 'name': 'Questionnaire Administration', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Lutetium Lu 177 Dotatate (protocolSection.armsInterventionsModule.interventions[].name)
• Capecitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Temozolomide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.